Imaging Choices in the Management of Colorectal Cancer Part 1

> Patrick Vos Department of Radiology St. Paul's Hospital Vancouver, BC





# Imaging Choices in the Management of Colorectal Ca

Review staging Colorectal Ca Local staging Lung and liver lesions

PART 2: PET/CT Dr. Pete Tonseth





# No time

Colon Ca Details local Rectal staging New Imaging Techniques (MR) Tumor regression post Ch/RT





### Local Staging Rectal Cancer



Kaur H et al. Radiographics 2012;32:389-409



©2012 by Radiological Society of North America

Rectal Ca Local Staging

Accuracy DRE T staging 58-88%

EUS Staging information changed the surgeon's original treatment plan based on CT in 31% of patients

> Schaffzin et al. Clin Colorectal Cancer. 2004;4:124-132. Harewood GC. Gastroenterology 2002; 123:24-32



## BCCA Rectal Cancer Group Guidelines

Clinical Stage 1 (T1, T2, N0, M0)

- Segmental resection. No preop radiation
- Local excision if favorable T1 lesion

#### Clinical Stage 2 (T3, T4, N0, M0)

- Preop short course radiation
- Segmental resection. Local excision contraindicated

#### Clinical Stage 3 (any T, N1, N2, N3, M0)

- Managed as for stage 2
- Preop radical preoperative chemoradiation may be indicated

#### Clinical Stage 4 (any T, any N, M1)

- Excision of primary tumor
- Chemoradiation
- Resection of metastatic lesion
- Fulguration/laser/ endoluminal radiation



BC Cancer Age

# BCCA Rectal Cancer Group Cancer Management Guidelines

- Complete colonoscopy
- Tumour height
- Accurate preoperative staging
- Preoperative CEA
- PET scan not recommended
- Core biopsy in patients with unresectable disease



# Accurate preoperative staging

- Location (height)
- TNM staging
- Free resection Margin TME

### **Tumor Location**

- Surgical planning
- Determine pre-op management

 Most distal location of the tumour is used to define tumour location Tumour Height Measurement

Decreasing order of reliability???

Rigid sigmoidoscopy
Flexible sigmoidoscopy/colonoscopy
Endorectal ultrasound (can overestimate)
DRE (low lying tumours)
CT or MRI



### **Relationship to anal sphincter**



Kaur H et al. Radiographics 2012;32:389-409

RadioGraphics

©2012 by Radiological Society of North America





#### Best imaging modality determined by T Stage

### **Endorectal Ultrasound**



http://www.medscape.org/viewarticle/



### **Rectal Cancer**

Advantage: High Spatial Resolution Differentiate T0-T1-T2-T3 In office





T3 rectal cancer

# ERUS Disadvantage:

Availability/Expertise High/low/obstructing tumors Discomfort Cannot see MRF May overestimate distance Overstaging: 20% T3-T4 actually T2

Sauer R, N Engl J Med. 2004;351:1731-1740.





Chun H et al. AJR 2006;187:1557-1562

©2006 by American Roentgen Ray Society



#### T2

### Transverse ERUS invading muscularis propria Perirectal tissue is clear

Chun H et al. AJR 2006;187:1557-156

©2006 by American Roentgen Ray Society

# T = Primary Tumor

### uT3:

 Tumor penetrates the entire thickness of the bowel wall and invades the perirectal tissues



# ERUS T0-T1

Meta analysis	Sens	Spec	
Tis Puli ( <i>Dig Dis Sci 10</i> )	97	96	
T1			
Bipat (Radiology 04)	94	86	
Puli (Ann S Onc 09)	88	98	



# MRI



### **MRI advantage:**

- High Spatial Resolution
- More available ERUS?
- Best Method to see MRF

Sauer R, N Engl J Med. 2004;351:1731-1740.



# MRI advantage:

- Reliable and reproducible technique with high specificity (92%) for:
  - relationship to the MRF
  - Depth tumor invasion outside muscularis propria

# MRI Disadvantage:

- Availability
- Claustrophobia etc
- No staging outside pelvis

Muthusamy VR, Chang KJ. Clin Cancer Res. 2007

# MRI Disadvantage:

- Expertise
- Interobserver variability
- Need High Resolution Images

- Limitations borderline T2-T3
- Overstaging T2 29-40%

Sauer R, N Engl J Med. 2004;351:1731-1740.



**T**?

Chun H et al. AJR 2006;187:1557-1562



©2006 by American Roentgen Ray Society



**T3**?



Chun H et al. AJR 2006;187:1557-1562





# **ERUS/MRI**

T2/T3	Sens	Spec
MRI	94/82%	70/75%
ERUS	94/90%	85/75%

Bipat et al. Radiology 2004



### **MRI=CT**



- Fast
- Available
- Staging entire chest/abd/pelvis

# Mesorectal Fascia CT





## **CT** Accuracy

Parameter	Stage $\leq T2$ (pT1, $n = 3$ ; pT2, $n = 10$ )		Stage T3 (pT3, n = 25)		Stage T4 (pT4, $n = 3$ )	
	Transverse Images Alone	Transverse and MPR Images Combined	Transverse Images Alone	Transverse and MPR Images Combined	Transverse Images Alone	Transverse and MPR Images Combined
Accuracy	90	93	85	90	80	98
Sensitivity	82	92	76	88	100	100
Specificity	93	93	100	94	79	97
Positive predictive value	82	86	100	96	27	75
Negative						
predictive value	93	96	73	83	100	76

#### Filippone A et al. Radiology 2004;231:83-90


### **CT disadvantage:**

Less detailed spatial and contrast resolution

Accuracy advanced T3-T4

79% to 94%

All stages

52% to 74%



Muthusamy VR. Clin Cancer Res. 2007





# **T4 Lesions**



Loss of fat plane between tumor and lower uterine segment

**Sacral invasion** 



# N = Regional Lymph Nodes

NX	Regional lymph nodes cannot be assessed
<b>N0</b>	No regional lymph node metastasis
N1	Metastasis in 1 to 3 regional lymph nodes
N2	Metastasis in 4 or more regional lymph nodes
N3	Metastasis in a lymph node along the course of a named vascular trunk

# N = Regional Lymph Nodes

Distribution depends on level of tumor:

**Upper Rectum** 

epicolic nodes  $\implies$  pararectal nodes  $\implies$  intermediate mesocolic nodes  $\implies$  principle IMA nodes

Lower Rectum

middle and inferior rectal vessels → hypogastric and obturator nodes → paraaortic nodes

#### common nodal pathways of tumor spread



Kaur H et al. Radiographics 2012;32:389-409



# **Nodal Criteria for Size?**

# N = Regional Lymph Nodes



# **Nodal Criteria for Size**

- Retroperitoneal
- Mesenteric
- Common Iliac
- External Iliac
- Internal Iliac
- Obturator
- Superior Rectal
- Pararectal
- Deep/Superficial Inguinal
- Lateral Sacral

**10 mm** 10 mm 9 mm **10 mm** 7 mm 8 mm 5 mm 3 mm **10** mm 7 mm

Nodal spread and micrometastasis within mesorectum

- 31 consecutive patients
- No chemo/radiation
- 21 T3
- 992 lymph nodes harvested
- metastasis found in 148 nodes

Wang C et al. World J Gastroenterol 2005 June 21

Nodal spread and micrometastasis within mesorectum

<1mm 7% <2mm 24% <5mm 70%

Wang C et al. World J Gastroenterol 2005 June 21

# Nodes Size criteria

#### Tradeoff

Size	Sens	Spec
3mm	78	59
10mm	3%	100%
	Brown G	. Br J Surg. 2003;90

# N=188 EUS/MR staged T3 N0

- Multicenter
- 188 pts
- T3 N0 ERUS/MRI
- preop Ch-RT

Guillem JG. J Clin Oncol. 2008 Jan 20

# N=188 EUS/MR staged T3 N0

 22% of patients undetected mesorectal LN involvement despite Ch-RT

Guillem JG. J Clin Oncol. 2008 Jan 20

### Nodal spread

Overall accuracy 60-80% No differences ERUS/MR/CT

T stage correlates with LN positivity T stage correlates with accuracy LN staging

Wang C et al. World J Gastroenterol 2005 June 21

# **Other criteria**

Amount not helpful

Kim JH. Eur J Radiol. 2004 Oct;52(1):78-83.



### Irregular Border and Mixed Signal Intensity

**Cancer Care** Ontario

### Reliability of imaging modalities for predicting lymph node involvement uncertain





Up to 20% of patients have involved nodes of less than 3mm





#### **Enlarged pararectal nodes**

#### **Enlarged left paraaortic node**

# N + = 100% positive

*Kim JH. Eur J Radiol. Oct 2004;52* 

# Conclusion

T stage assessment is fairly accurate

N stage is only moderately effective whatever modality is used

# Conclusion

- New techniques
  - $-\mathbf{DWI}$
  - Specific contrast agents
  - USPIO, Gadofosveset

#### - PET/CT PET/MR ??

### M = Distant Metastases

MX = Distant metastases cannot be assessed

M0 = No distant metastases

M1 = Distant metastases

# **Distant Metastases**



**Enlarged portocaval node** 

Liver metastasis

### Distant disease and Follow-up

- Generally CT sufficient
- Follow-up: How often? How long?
- What to do with incidental findings?
  Liver: subcentimeter lesions TSTC
  Lung: small nodules ILN

# What to do with incidental findings?

#### -Liver: TSTC



### –Lung: ILN



Prevalence and importance of small hepatic lesions found at CT in patients with cancer

- CT 2,978 patients with cancer
- Benign: 303/2978 (80.2%) patients
- Malignant 44 (11.6%) patients
- Indeterminate 31 (8.2%) (short FU)
- CRC: mets in 14% pts with CRC

Schwartz LH. Radiology. 1999 Jan;210(1):71-4.

Prevalence and importance of small hepatic lesions found at CT in patients with cancer

- CONCLUSION:
- small hepatic lesions in patients with cancer majority is benign
- metastases in 14 % of patient

Schwartz LH. Radiology. 1999 Jan;210(1):71-4.

Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer

- 70/419 patients (16.7%) small liver lesions TSTC
- 46 patients (65.7%) subsequent imaging of their liver lesions
- 41 (89.1%) stable likely benign
- 5 (10.9%) progression suggestive of mets

Lim GH. Dis Colon Rectum. 2009 Aug;52(8)

# **CT follow-up hypoattenuating small liver lesions in patients with rectal ca**

- 616 consecutive patients
- 70 patients with 163 hepatic lesions
- Patients stable 80%
- Lesions Stable 90.8%
- No significant difference in results was found for patients stratified according to T-stage

Tan CH. Am J Clin Oncol. 2011 Aug;34(4)

# **CT follow-up hypoattenuating small liver lesions in patients with rectal ca** • CONCLUSION

- majority of small hypoattenuating liver lesions remain stable and treated as benign lesions
- Closely followed for at least 1 year after completion of therapy

Tan CH. Am J Clin Oncol. 2011 Aug;34(4)



- retrospective study breast ca
- 1012 woman CT
- 277 pts TSTC but no definite liver metastases at initial CT

 92.7%-96.9% the lesions represented a benign finding

Hanan I et al. Radiology. 2005, 235(3):



# TSTC

### **Problem solving**

- US: small cysts
- MRI: hepatocyte-specific contrast agents Gd-EOB-DTPA (Primovist)

Follow-up

# colorectal cancer metastasis

	CECT	MRI	PET	PET-CT
Sens per lesion	69-79%	75-85%	67-91%	55-75%
Spec per patient	93-96%	90-95%	93-98%	93-99%

Frankel et al. J Gastrointest Oncol. 2012 Niekel et al. Radiology. 2010 Dec

# Lung Nodules ILN



Screening studies, up to 51% of smokers aged 50 years or older have pulmonary nodules on CT scans
### CT staging of colorectal cancer: what do you find in the chest?

- 568 CRC complete CT staging
- 31 (6%) had lung metastases
- 353 (68.7%) no evidence of metastases
- 130 (25.3%) had indeterminate lung nodules

  12 patients subsequently confirmed as mets

  3% major non-metastatic finding (PE, Lung Ca)

McQueen, Clin Radiol. 2012 Apr;67(4)

CT staging of colorectal cancer: what do you find in the chest? CONCLUSIONS:

1. Thoracic CT altered initial TNM stage in fewer than 1% of CRC patients

2. detection of significant incidental chest disease and the establishment of an imaging baseline are useful outcomes of this imaging strategy

3. staging examinations 25% ILNs

McQueen, Clin Radiol. 2012 Apr;67(4)

- A review of studies assessing chest staging modalities for patients with CRC
- Majority were case series
- Low pick-up rate for CXR
- Increased detection rates chest CT

Rectal ca: incidence lung mets 10%-18% Colon cancer: incidence lung mets 5-6%

Clinical benefit of increased detection rates not clear Incidence ILN 4%-42%

Majority (≥ 70%) of ILN's did not have any clinical significance

Incidence of synchronous liver and pulmonary metastases 45% to 70%

No evidence superiority of PET/CT vs CT for the detection of pulmonary metastases or characterization of ILL

- CONCLUSION:
- CT scanning increases the detection rates for ILL and pulmonary metastases

 Clinical benefit increased detection rates not clear

Paucity of data optimal chest staging strategy



Mets Colon ca





#### Best choice Imaging depends on T stage

### Suggestions: Imaging Strategy

T0-T1 ERUS T1-T2-T3 Clinical **ERUS-MRI** CT T3-T4 MRI?

### Summary

- Imaging often complimentary
- Overstaging: ERUS + MRI
- Accuracy LN 60-80%



- Have a plan:
  - Liver: TSTC
  - Lung: ILN's

 Clinical benefit of increased detection rates not clear



#### Standardized/Template reporting?

sand	er Care Ontari	O Canadian 5	oclété
Actio	n Cancer Ontari	io Society d	Society du cancer
This document was developed by Drs Elser Al-Sukhri, Laurent Miliot, Mark Prultman, Gine Brown, Seline Schmocker and Erin Kannedy for the Cencer Serv Innovation Partnership — a joint initiative of Cancer Care Ontario and the Cenadian Cancer Society			
1. MRI PROTOCOL Overall image quali	ty: 🗌 Adequate	Suboptimal Non-diagno:	stic
2. TUMOUR LOCAT Turnour location	FION (from anal verge):	Low (0-5.0 cm) Mid (5.1-10.0 cm) High (10.1-15.0 cm)	
Distance of the I Distance of lowe Relationship to	lowest extent of tumour est extent of tumour fro anterior peritoneal refle	r from anal verge:cm m top of the anal sphincter:cm ction:AboveAt or straddles	Below Not able to asse
Circumferential ext Craniocaudad exter Mucinous:	ent/location (clock face) t:cm NoYes	rectal fat)	
T4" "Please indicate strue	ctures with possible invasi	on:{see list below	ġ.
the second se	PRIVE SIDE WALL	BONE/VASCULAR	OTHER Anterior peritonesi reflection
GU bladder left ureter; right ureter prostate urerus svigine	Obtunctor Internus Picifornis LEVATOR ANI Pabococogeus Heococcygeus Coccygeus	left internal fluc vessels; right internal fluc vessels left atternal fluc vessels; right external fluc vessels	
GU bladder left uneter; right ander protate vietus vietus nii. <u>For low rectal tu</u> ls the lower extent	Obtainator Internus Pictores LEVATOR ANI Pabococognus Heococognus Cocognus Cocognus mours (0 - 5 cm) only: of the tumour at or belo	left Internal Tile: vessels; right internal Tile: vessels left artsmal Tile: vessels; right external Tile: vessels	No 🗌 Yes*
au sledder left ureter; right under orotate vegine ii. <u>For low rectol tu</u> is the lower extent " <u>If yes</u> , please comj of puborectalis: Possible confiner	Obtained in the must Pictores LEVATOR ANI Paboocorgens Heococrygens Cocrygens Cocrygens Cocrygens mours (0 - 5 cm) only: of the tumour at or belo plete the following section the to the submuces on	The transmitter of the public component of the definite involvement of internal component of the definite involvement of the definite involvem	No Yes* e tumour below the top borde

#### **Cancer Care** Ontario

#### 5. DISTANCE TO THE MRF AND EXTRAMURAL DEPTH OF INVASION (EMD)

i)	Shortest distance of the definitive tumour border to the MRF = mm [ $\underline{or} \Box$ unable to estimate $\underline{or} \Box$ not applicable (involving the peritonealized portion of the rectum or T4a)]		
ii)	Extramural depth of invasion (EMD) at this level = mm [Record 0 mm for T1 and T2 tumours]		
iii)	Are there any tumour spiculations closer to the MRF? No Yes*		
	*If yes, please specify distance = mm and location (on clock face)		
iv)	Is there any other component of the tumour (any T1-3) closer to the MRF?		
	*If yes, please specify distance = mm and location (on clock face)		
6.	EXTRAMURAL VASCULAR INVASION (EMVI)		
	EMVI: Absent Equivocal Present		
7.	MESORECTAL LYMPH NODES AND TUMOUR DEPOSITS		
	Any suspicious mesorectal lymph nodes and/or tumour deposits? $\Box$ No $\Box$ Yes* (suspicious = irregular border, mixed signal intensity and/or $\geq$ 8 mm)		
	*If yes: (please complete a and b)		
	Cancer Care Ontario		



















### T3 CRM+

### ∽ The end ≪